Ptgs2 Cox 2 Protein Cyclooxygenase 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Symbol | PTGS2 |
| Protein Name | Prostaglandin-Endoperoxide Synthase 2 |
| Common Name | Cyclooxygenase-2 (COX-2) |
| Molecular Weight | 70 kDa |
| Enzyme Class | EC 1.14.99.1 - Peroxidase |
| Associated Diseases | AD, PD, ALS, HD, Stroke, Rheumatoid Arthritis, Cancer |
PTGS2 (Prostaglandin-Endoperoxide Synthase 2), commonly known as Cyclooxygenase-2 (COX-2), is a key enzyme in prostaglandin biosynthesis that catalyzes the conversion of arachidonic acid to prostaglandin H2 (PGH2). Unlike the constitutively expressed COX-1, COX-2 is an inducible enzyme upregulated in response to inflammatory stimuli, growth factors, and pathological conditions. In the central nervous system, COX-2 plays complex roles in neuroinflammation, synaptic plasticity, and neuronal survival, making it a critical player in neurodegenerative diseases.
COX-2 is a 70 kDa integral membrane protein with a distinctive structure:
COX-2 is elevated in AD brain, particularly in neurons surrounding amyloid plaques. The enzyme contributes to neuroinflammation through PGE2 production, promotes amyloidogenesis, and may accelerate tau pathology. However, COX-2 also has neuroprotective effects through PGE2-mediated signaling.
COX-2 upregulation in PD substantia nigra correlates with dopaminergic neuron loss. Inhibition provides neuroprotection in experimental models. The enzyme links neuroinflammation to α-synuclein aggregation.
Elevated COX-2 in ALS spinal cord and motor cortex. Contributes to excitotoxicity through prostaglandin-mediated mechanisms. Clinical trials of COX-2 inhibitors have shown mixed results.
COX-2 increased in HD brain and models. PGE2 accumulation contributes to neuronal dysfunction. COX-2 inhibition shows benefits in mouse models.
COX-2 induced dramatically following cerebral ischemia. Contributes to excitotoxic damage and inflammation. COX-2 inhibitors have neuroprotective potential post-stroke.
| Drug | Selectivity | Neuroprotective? |
|---|---|---|
| Celecoxib | COX-2 selective | Mixed results |
| Rofecoxib | COX-2 selective | Limited benefit |
| Ibuprofen | Non-selective | Promising preclinical |
| Minocycline | Non-COX | Anti-inflammatory |
The study of Ptgs2 Cox 2 Protein Cyclooxygenase 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.